You are hereHome › Custirsen (OGX-011) Phase 2...
Custirsen (OGX-011) Phase 2 Clinical Trials Results
Our Phase 1 clinical trials evaluated the safety and established the recommended Phase 2 dose of OGX-011 in combination with either docetaxel chemotherapy (two different schedules), gemcitabine/cisplatin chemotherapy or hormone ablation therapy. In all clinical trials, 640 mg was established as the Phase 2 dose.
We have conducted five Phase 2 clinical trials of OGX-011 to further evaluate the safety and efficacy of OGX-011 in combination with various cancer therapies for prostate, non-small cell lung and breast cancer, as further described below.
This section is intended specifically for health care professionals. Information is provided for educational use only, based on pre-clinical and clinical data of curstirsen. Custirsen is not approved for commercial use and is only available for investigational use in approved clinical trials.